Catherine Thiéblemont

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste et al. · Blood · 2010 · 1.5K citations · Full text

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · Blood · 2007 · 899 citations · Full text

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson et al. · Journal of Clinical Oncology · 2019 · 591 citations · Full text

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

Frédéric Peyrade, Fabrice Jardin, Catherine Thiéblemont et al. · The Lancet Oncology · 2011 · 530 citations

Hematological Malignancy, Lymphoid Neoplasia, Autoimmune Disease +8

Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed

Catherine Thiéblemont, Françoise Berger, Charles Dumontet et al. · Blood · 2000 · 514 citations